

DERIVATIVES OF 2-BENZYLIDENECYCLOHEXANONE
AS POTENTIAL ANTINEOPLASTIC AGENTS

A Thesis

Submitted to the Faculty of Graduate Studies
in Partial Fulfillment of the Requirements
for the Degree of
Doctor of Philosophy
in Pharmacy

by

Wayne Arnold Turner B.S.P., M.Sc.
Saskatoon, Saskatchewan
(c) 1972. W.A. Turner

The author has agreed that the Library, University of Saskatchewan, may make this thesis freely available for inspection. Moreover, the author has agreed that permission for extensive copying of this thesis for scholarly purposes may be granted by the professor or professors who supervised the thesis work recorded herein or, in their absence, by the Head of the Department or the Dean of the College in which the thesis work was done. It is understood that due recognition will be given to the author of this thesis and to the University of Saskatchewan in any use of the material in this thesis. Copying or publication or any other use of the thesis for financial gain without approval by the University of Saskatchewan and the author's written permission is prohibited.

Requests for permission to copy or to make other use of material in this thesis in whole or in part should be addressed to:

Dean of the College of Pharmacy,
University of Saskatchewan,
SASKATOON, Canada

ACKNOWLEDGEMENTS

The author wishes to sincerely thank Dr. J. R. Dimmock for his personal interest, guidance, and encouragement during the course of the research work and in the preparation of this thesis. The author would also like to thank Dr. R. G. Sutherland, Department of Chemistry, for his valuable assistance.

The mass spectral work was done in collaboration with Dr. P. J. Smith, Department of Chemistry, and his enthusiasm and valuable contributions are gratefully acknowledged.

The research was supported by Medical Research Council of Canada Studentships and Canadian Foundation for the Advancement of Pharmacy Fellowships.

Screening results were carried out by the Drug Research and Development branch of the National Cancer Institute, Bethesda, Maryland, and by Smith Kline and French Laboratories, Philadelphia.

T O S A N D R A

ABSTRACT

The aim of this research was to prepare some substituted 2-benzylidenecyclohexyl isothiocyanates, which would be screened against L-1210 lymphoid leukemia and the KB tumor. The first step in the synthesis involved the preparation of substituted (E)-2-benzylidenecyclohexanones, which are α,β -unsaturated ketones, a class of compounds known to have alkylating properties. Only the substituted (E,E)-2,6-bis-(dichlorobenzylidene)cyclohexanones were isolated in the syntheses designed to yield (E)-2-(dichlorobenzylidene)cyclohexanones. All benzylidene derivatives were submitted for screening. The unsubstituted compound, (E)-2-benzylidenecyclohexanone, has a high level of activity against the KB tumor in vitro, and a low level of toxicity in mice.

Ultraviolet irradiation resulted in isomerization of the substituted (E)-2-benzylidenecyclohexanones to the Z isomers. (Z)-2-Benzylidenecyclohexanone was isolated from the ultraviolet irradiation of the E isomer.

Ultraviolet spectroscopy and the Braude equation were employed to study the degree of coplanarity of the conjugated system for some of the benzylidene derivatives.

The mass spectra of the substituted (E)-2-benzylidenecyclohexanones and the substituted (E,E)-2,6-bis-benzylidenecyclohexanones were examined in detail. One of the major fragmentation pathways involved an intramolecular attack by the carbonyl oxygen on the ortho position

of the aromatic ring, resulting in the formation of a benzopyrylium ion.

The second step in the synthesis involved the preparation of the substituted (E)-2-benzylidenecyclohexanone oximes from the corresponding ketones. The mass spectra of the oximes were also examined. A major fragmentation pathway involved an intramolecular attack of the nitrogen of the oxime function on the ortho position of the aromatic ring, analogous to a major fragmentation pathway of the ketones.

Lithium aluminum hydride reduction of the substituted (E)-2-benzylidenecyclohexanone oximes was expected to yield the substituted (E)-2-benzylidenecyclohexylamines. However, high yields of substituted 1-benzyl-1,2-epiminocyclohexanes were obtained. Aziridines have a wide range of biological activity, including anticancer activity. The substituted 1-benzyl-1,2-epiminocyclohexanes were submitted for screening against L-1210 lymphoid leukemia and the KB tumor.

Treatment of 1-benzyl-1,2-epiminocyclohexane with acetic anhydride under reflux resulted in pyrolytic cis-elimination, with the formation of 3-acetamido-2-benzyl-1-cyclohexene.

The Leuckart Reaction was employed in an attempt to convert (E)-2-benzylidenecyclohexanone directly to the corresponding primary amine, (E)-2-benzylidenecyclohexylamine. Several reaction systems were investigated, each yielding the desired amine in only trace amounts.

A third synthesis was attempted, which was to involve the lithium aluminum hydride reduction of the substituted (E)-2-benzylidene-

cyclohexanones to the corresponding unsaturated alcohols, conversion of the alcohols to the tosylate derivatives, formation of the azides from the tosylates, and lithium aluminum hydride reduction of the azides to give the (E)-2-benzylidenecyclohexylamines. The amines could then be used in the Hofmann mustard oil reaction to form the (E)-2-benzylidenecyclohexyl isothiocyanates.

Reduction of (E)-2-benzylidenecyclohexanone with lithium aluminum hydride gave (E)-2-benzylidenecyclohexanol. p-Toluenesulfonyl chloride did not react with this alcohol at room temperature or under ether reflux. Treatment of the lithium salt of (E)-2-benzylidene-cyclohexanol with p-toluenesulfonyl chloride gave the elimination product, 3-benzylidene-1-cyclohexene, in high yield.

TABLE OF CONTENTS

	<u>Page</u>
ACKNOWLEDGEMENTS.....	iii
ABSTRACT.....	iv
LIST OF TABLES.....	xiv
LIST OF FIGURES.....	xv
LIST OF SCHEMES.....	xvi
1. INTRODUCTION.....	1
1.1 Chemotherapy of cancer.....	1
1.2 The aims of the present investigation.....	3
2. DISCUSSION OF THE EXPERIMENTAL WORK.....	20
2.1 Preparation of substituted 2-benzylidenecyclohexanones and substituted 2,6- <u>bis</u> -benzylidenecyclohexanones.....	20
2.1.1 Preparation of substituted 2-benzylidenecyclohexanones.....	20
2.1.2 Preparation of substituted 2,6- <u>bis</u> -benzylidene-cyclohexanones.....	22
2.1.2.1 Proposed mechanism involved in the formation of the <u>bis</u> -compounds.....	22
2.1.3 Stereochemistry of the substituted 2-benzylidene-cyclohexanones and substituted 2,6- <u>bis</u> -benzylidene-cyclohexanones.....	24
2.1.4 Isomerization of substituted 2-benzylidenecyclohexanones.....	28
2.1.5 Calculation of the interplanar angle (θ) for substituted 2-benzylidenecyclohexanones and substituted 2,6- <u>bis</u> -benzylidenecyclohexanones.....	32

2.1.6	Mass spectra of substituted 2-benzylidenecyclohexanones and substituted 2,6- <u>bis</u> -benzylidenecyclohexanones.....	37
2.1.6.1	Introduction.....	37
2.1.6.2	Mass spectrum of (<u>E</u>)-2-benzylidenecyclohexanone.....	39
2.1.6.3	Mass spectra of the substituted (<u>E</u>)-2-benzylidenecyclohexanones.....	53
2.1.6.4	Mass spectra of the substituted (<u>E</u> , <u>E</u>)-2,6- <u>bis</u> -benzylidenecyclohexanones.....	58
2.2	Preparation of substituted (<u>E</u>)-2-benzylidenecyclohexanone oximes.....	61
2.2.1	Configuration of the oximes.....	61
2.2.2	Gas-liquid chromatography (glc) and thin-layer chromatography (tlc) of the oximes.....	63
2.2.3	Mass spectra of substituted (<u>E</u>)-2-benzylidenecyclohexanone oximes.....	65
2.2.3.1	Introduction.....	65
2.2.3.2	Results and discussion.....	71
2.3	Reduction of substituted 2-benzylidenecyclohexanone oximes.....	78
2.3.1	Preparation of 1-benzyl-1,2-epiminocyclohexane.....	78
2.3.2	Preparation of related substituted 1-benzyl-1,2-epiminocyclohexanes.....	90
2.3.3	Attempted reduction of (<u>E</u>)-2-benzylidenecyclohexanone oxime with other reducing agents.....	91
2.3.4	Structure of the aziridines.....	92
2.3.5	Mechanism of action and biological activity of aziridine derivatives.....	93
2.4	Attempted preparation of the N-acetyl derivative of 1-benzyl-1,2-epiminocyclohexane.....	98

2.4.1	Pyrolytic <u>cis</u> -elimination of aziridines.....	98
2.5	Other attempts to prepare (<u>E</u>)-2-benzylidenecyclohexyl isothiocyanate.....	103
2.5.1	Preparation of (<u>E</u>)-2-benzylidenecyclohexylamine by the Leuckart reaction.....	103
2.5.2	Attempted preparation of (<u>E</u>)-2-benzylidenecyclohexylamine via an azide.....	105
2.5.2.1	Preparation of (<u>E</u>)-2-benzylidenecyclohexanol.....	106
2.5.2.2	Attempted preparation of (<u>E</u>)-2-benzylidenecyclohexyl <u>p</u> -toluenesulfonate.....	113
2.5.2.3	Attempted preparation of (<u>E</u>)-2-benzylidenecyclohexyl azide.....	114
3.	DISCUSSION OF THE SCREENING RESULTS.....	116
3.1	Introduction.....	116
3.2	Screen against L-1210 lymphoid leukemia.....	117
3.3	Screen against the KB (Eagle) cell culture.....	122
3.4	Screen against adjuvant-induced arthritis.....	125
3.5	Antiobesity screen.....	126
3.6	Antiviral screen.....	127
3.7	Gastric acid secretion.....	127
3.8	General test for pharmacological effects.....	128
4.	DESCRIPTION OF THE EXPERIMENTAL WORK.....	129
4.1	Preparation of substituted 2-benzylidenecyclohexanones.....	129
4.1.1	Preparation of (<u>E</u>)-2-benzylidenecyclohexanone.....	129
4.1.2	Preparation of (<u>Z</u>)-2-benzylidenecyclohexanone.....	130
4.1.3	Preparation of (<u>E</u>)-2-(2-chlorobenzylidene)cyclohexanone.....	132
4.1.4	Attempted preparation of (<u>Z</u>)-2-(2-chlorobenzylidene)-cyclohexanone.....	133

4.1.5	Preparation of (<u>E</u>)-2-(3-chlorobenzylidene)cyclohexanone.....	135
4.1.6	Preparation of (<u>E</u>)-2-(4-chlorobenzylidene)cyclohexanone.....	136
4.1.7	Preparation of (<u>E</u>)-2-(4-dimethylaminobenzylidene)-cyclohexanone.....	138
4.1.8	Preparation of (<u>E</u>)-2-(4-dimethylaminobenzylidene)-cyclohexanone methiodide.....	139
4.2	Preparation of substituted 2,6- <u>bis</u> -benzylidenecyclohexanones.....	141
4.2.1	Preparation of (<u>E,E</u>)-2,6- <u>bis</u> -(2,6-dichlorobenzylidene)-cyclohexanone.....	141
4.2.2	Preparation of 2-(α -hydroxy-2,6-dichlorobenzyl)cyclohexanone.....	142
4.2.3	Preparation of (<u>E,E</u>)-2,6- <u>bis</u> -(2,4-dichlorobenzylidene)-cyclohexanone.....	144
4.2.4	Preparation of (<u>E,E</u>)-2,6- <u>bis</u> -(3,4-dichlorobenzylidene)-cyclohexanone.....	145
4.2.5	Preparation of (<u>E,E</u>)-2,6- <u>bis</u> -(4-dimethylamino-benzylidene)cyclohexanone.....	146
4.3	Preparation of substituted 2-benzylidenecyclohexanone oximes.	147
4.3.1	Preparation of (<u>E</u>)-2-benzylidenecyclohexanone oxime.	147
4.3.2	Preparation of (<u>Z</u>)-2-benzylidenecyclohexanone oxime.	148
4.3.3	Preparation of (<u>E</u>)-2-(2-chlorobenzylidene)-cyclohexanone oxime.....	149
4.3.4	Preparation of (<u>E</u>)-2-(4-chlorobenzylidene)-cyclohexanone oxime.....	150
4.3.5	Preparation of (<u>E</u>)-2-(4-dimethylaminobenzylidene)-cyclohexanone oxime.....	151
4.3.6	Preparation of the acetate of (<u>E</u>)-2-benzylidene-cyclohexanone oxime.....	152
4.4	Reduction of substituted 2-benzylidenecyclohexanone oximes.	153

4.4.1	Preparation of 1-benzyl-1,2-epiminocyclohexane.....	153
4.4.1.1	Reduction of (<u>E</u>)-2-benzylidenecyclohexanone oxime with lithium aluminum hydride.....	153
4.4.1.2	Reduction of (<u>E</u>)-2-benzylidenecyclohexanone oxime with lithium aluminum deuteride.....	154
4.4.1.3	Reduction of (<u>E</u>)-2-benzylidenecyclohexanone oxime with lithium borohydride.....	155
4.4.1.4	Reduction of (<u>Z</u>)-2-benzylidenecyclohexanone oxime with lithium aluminum hydride.....	155
4.4.1.5	Reduction of the acetate of (<u>E</u>)-2-benzylidenecyclohexanone oxime with lithium aluminum hydride.....	156
4.4.2	Attempted reduction of (<u>E</u>)-2-benzylidenecyclohexanone oxime with other reducing agents.....	156
4.4.2.1	Attempted reduction of (<u>E</u>)-2-benzylidenecyclohexanone oxime with sodium borohydride.	156
4.4.2.2	Attempted reduction of (<u>E</u>)-2-benzylidenecyclohexanone oxime with sodium trimethoxyborohydride.....	158
4.4.2.3	Attempted reduction of (<u>E</u>)-2-benzylidenecyclohexanone oxime with lithium tri-(<i>t</i> -butoxy)-aluminum hydride.....	158
4.4.2.4	Attempted reduction of (<u>E</u>)-2-benzylidenecyclohexanone oxime with sodium in ethanol.....	159
4.4.2.5	Attempted reduction of (<u>E</u>)-2-benzylidenecyclohexanone oxime with zinc and glacial acetic acid.....	159
4.4.3	Preparation of 1-(2-chlorobenzyl)-1,2-epiminocyclohexane	160
4.4.3.1	Reduction of (<u>E</u>)-2-(2-chlorobenzylidene)cyclohexanone oxime with lithium aluminum hydride.....	160
4.4.4	Preparation of 1-(4-chlorobenzyl)-1,2-epiminocyclohexane.....	162
4.4.4.1	Reduction of (<u>E</u>)-2-(4-chlorobenzylidene)cyclohexanone oxime with lithium aluminum hydride.	162

4.4.5	Preparation of 1-(4-dimethylaminobenzyl)-1,2-epiminocyclohexane.....	163
4.4.5.1	Reduction of (<u>E</u>)-2-(4-dimethylaminobenzylidene)-cyclohexanone oxime with lithium aluminum hydride.....	163
4.5	Preparation of derivatives of 1-benzyl-1,2-epiminocyclohexane.....	166
4.5.1	Preparation of 3-acetamido-2-benzyl-1-cyclohexene...	166
4.5.2	Preparation of 3-acetamido-2-benzyl- α - <u>d</u> -1-cyclohexene- <u>3-d</u>	167
4.5.3	Preparation of 1-acetamido-2-benzylcyclohexane.....	168
4.6	Preparation of (<u>E</u>)-2-benzylidenecyclohexylamine by the Leuckart Reaction.....	170
4.6.1	Reaction of (<u>E</u>)-2-benzylidenecyclohexanone with formamide.....	170
4.6.2	Reaction of (<u>E</u>)-2-benzylidenecyclohexanone with formamide and formic acid.....	171
4.6.3	Reaction of (<u>E</u>)-2-benzylidenecyclohexanone with concentrated ammonia solution and formic acid.....	172
4.6.4	Reaction of (<u>E</u>)-2-benzylidenecyclohexanone with ammonium formate and formic acid.....	173
4.7	Preparation of (<u>E</u>)-2-benzylidenecyclohexanol.....	174
4.7.1	Reduction of (<u>E</u>)-2-benzylidenecyclohexanone with lithium aluminum hydride.....	174
4.7.2	Reduction of (<u>E</u>)-2-benzylidenecyclohexanone with lithium aluminum deuteride.....	176
4.7.3	Reduction of (<u>E</u>)-2-benzylidenecyclohexanone with sodium borohydride.....	177
4.7.4	Reduction of (<u>E</u>)-2-benzylidenecyclohexanone with sodium trimethoxyborohydride.....	178
4.8	Preparation of (<u>Z</u>)-2-benzylidenecyclohexanol.....	179

4.8.1	Reduction of (Z)-2-benzylidenecyclohexanone with lithium aluminum hydride.....	179
4.8.2	Ultraviolet irradiation of (E)-2-benzylidenecyclohexanol.....	180
4.9	Preparation of 2-benzylcyclohexanol.....	181
4.9.1	Catalytic reduction of (E)-2-benzylidenecyclohexanol.	181
4.10	Preparation of (E)-3-benzylidene-1-cyclohexene.....	182
4.10.1	Acid-catalyzed dehydration of (E)-2-benzylidene-cyclohexanol with <i>p</i> -toluenesulfonic acid.....	182
4.10.2	Acid-catalyzed dehydration of (E)-2-benzylidene-cyclohexanol with sulfuric acid.....	183
4.11	Attempted preparation of (E)-2-benzylidenecyclohexyl <i>p</i> -toluenesulfonate.....	184
4.11.1	Reaction of (E)-2-benzylidenecyclohexanol with <i>p</i> -toluenesulfonyl chloride.....	184
4.11.2	Reaction of the lithium salt of (E)-2-benzylidene-cyclohexanol with <i>p</i> -toluenesulfonyl chloride.....	185
4.12	Attempted preparation of (E)-2-benzylidenecyclohexyl azide.	187
5:	APPENDIX.....	188
6:	REFERENCES.....	192

LIST OF TABLES

<u>Table No.</u>		<u>Page</u>
I	Ultraviolet spectra of substituted 2-benzylidene-cyclohexanones.....	33
II	Ultraviolet spectra of substituted 2,6- <u>bis</u> -benzylidene-cyclohexanones.....	34
III	Relative intensity and <u>m/e</u> values of the principal ions observed in the 70 eV mass spectra of compounds in series 1.....	40
IV	Relative intensity and <u>m/e</u> values of the principal ions observed in the 70 eV mass spectra of compounds in series 2.....	41
V	M-1/M and M-Cl/M ratios at 70 eV for the substituted (E)-2-benzylidenecyclohexanones and a series of mono-substituted 1-phenyl-1-nonen-3-ones.....	42
VI	M-1/M and M-Cl/M ratios at 70 eV for the substituted (E,E)-2,6- <u>bis</u> -benzylidenecyclohexanones and a series of substituted 1-phenyl-1-nonen-3-ones.....	43
VII	Major peaks in the mass spectra of aziridines.....	86
VIII	Structures of compounds for which screening results are available (Series 1).....	118
IX	Structures of compounds for which screening results are available (Series 2).....	118
X	<u>In vivo</u> screening results against L-1210 lymphoid Leukemia.....	120
XI	<u>In vitro</u> screening results against the KB cell culture.....	124

LIST OF FIGURES

<u>Figure No.</u>		<u>Page</u>
1	Mass spectrum of (<u>E</u>)-2-benzylidenecyclohexanone....	44
2	Mass spectrum of (<u>E</u>)-2-(2-chlorobenzylidene)- cyclohexanone	45
3	Mass spectrum of (<u>E,E</u>)-2,6- <u>bis</u> -benzylidene- cyclohexanone	46
4	Mass spectrum of (<u>E,E</u>)-2,6- <u>bis</u> -(2,6-dichloro- benzylidene)cyclohexanone	47
5	Mass spectrum of (<u>E</u>)-2-benzylidenecyclohexanone oxime	66
6	Mass spectrum of (<u>E</u>)-2-(2-chlorobenzylidene)- cyclohexanone	67
7	Mass spectrum of (<u>E</u>)-2-(4-chlorobenzylidene)- cyclohexanone oxime	68
8	Mass spectrum of (<u>E</u>)-2-(4-dimethylaminobenzylidene)- cyclohexanone oxime	69
9	Mass spectrum of (<u>E</u>)-2-benzylidenecyclohexanone oxime acetate	70

LIST OF SCHEMES

<u>Scheme No.</u>		<u>Page</u>
1	Proposed route for the synthesis of substituted 2-benzylidenecyclohexyl isothiocyanates.....	10
2	Isomerization of 2-(2-chlorobenzylidene)cyclohexanone by acid.....	31
3	Mass spectral fragmentation of (<u>E</u>)-2-benzylidene-cyclohexanone.....	49
4	Mass spectral fragmentation of (<u>E</u>)-2-benzylidene-cyclohexanone.....	50
5	Mass spectral fragmentation of (<u>E</u>)-2-benzylidene-cyclohexanone.....	51
6	Mass spectral fragmentation of (<u>E,E</u>)-2,6- <u>bis</u> -(3,4-dichlorobenzylidene)cyclohexanone.....	60
7	Mass spectral fragmentation of an oxygen atom from aliphatic and aromatic ketoximes.....	76
8	Mass spectral fragmentation of 1-benzyl- <u>α</u> - <u>d</u> -1,2-epiminocyclohexane- <u>2</u> - <u>d</u>	87
9	Proposed route for the synthesis of (<u>E</u>)-2-benzylidene-cyclohexyl isothiocyanate.....	107

I. INTRODUCTION


1.1 Chemotherapy of cancer

Cancer is the malignant unrestrained proliferation of somatic cells. Leukemia is an uncontrolled multiplication of the leukoblastic tissues, or immature leukocytes, which generally leads to an increase in the white cells of the blood. The two major types of leukemia are myelogenous leukemia and lymphatic leukemia. In myelogenous leukemia there is an increase in the number of neutrophils, eosinophils, or basophils whereas lymphatic leukemia involves a proliferation of lymphoid cells only (Boyd, 1967). Chemotherapy has been used quite extensively in the treatment of leukemic patients since often the disease is too widespread for surgical treatment.


The development of chemotherapeutic agents has provided an additional choice of therapy for the treatment of cancer, supplementing surgery and radiation in the control of the disease. The principal classes of drugs that have been found useful in the treatment of cancer are the alkylating agents, antimetabolites, natural products such as the vinca alkaloids, antibiotics, and hormones.

The three major types of alkylating agents used in the chemotherapy of neoplastic diseases are the nitrogen mustards, the ethyleneimines, and the alkyl sulfonates, represented respectively by mechloroethamine (1),


triethylenemelamine (2), and busulfan (3).



(1)



(2)




(3)

These alkylating agents can readily form covalent linkage with various nucleophilic substances, including such biologically important moieties as the sulfhydryl and carboxyl groups of proteins, and the phosphate and imidazole groups of nucleic acids. Studies on the interaction of alkylating agents with DNA have shown that the

(1966) found that phenyl isothiocyanate and benzyl isothiocyanate have significant fungistatic activity and some tuberculostatic and ascaricidal activity. He also found tuberculostatic and ascaricidal activity in allyl isothiocyanate and cyclohexyl isothiocyanate. In addition, benzyl isothiocyanate was shown to have bacteriostatic activity.


Isothiocyanates combine with nucleophilic groups such as sulfhydryl, amino, and hydroxyl functions as shown below. For example, cyclohexyl




isothiocyanate has been shown to combine with hydroxyl and amino groups in vitro (Zahradnik, 1959). Allyl isothiocyanate combines with aromatic amines such as aniline and N-ethylaniline to give the corresponding allylphenylthioureas (Miskidzh'yan and Gladyshevskaya, 1962) and reacts with such aliphatic amines as methylamine, ethylamine, and isopropylamine to form the corresponding allylalkylthioureas (Miskidzh'yan, 1960). The addition of amines to isothiocyanates is generally much faster than the addition of the corresponding alcohols. Rao (1963) investigated the addition of various alkyl alcohols to 4-bromophenyl isothiocyanate to form the corresponding thiourethans (thiocarbamates).

Bacq and Fischer (1946) showed that allyl isothiocyanate reacts with the sulfhydryl groups of ovalbumin. Cattle serum, cysteine, and thioglycolate inhibit the antimicrobial activity of isothiocyanates which suggests that these compounds exert their antimicrobial activity by an intracellular inactivation of sulfhydryl enzymes (Zsolnai, 1966). The fungicidal activity of ethylene bisdithiocarbamic acid (4) is attributed to combination of the isothiocyanate (5), formed upon degradation, with essential sulfhydryl groups (Sijpesteijn and van der Kerk, 1954).

Alkylating agents are thought to react at the cellular level by S_N1 and S_N2 mechanisms. The rate of reaction by the S_N1 mechanism depends on the rate of formation of the carbonium ion which is itself dependent on the stability of the carbonium ion. Allylic derivatives give rise to more stable carbonium ions than alkyl derivatives due to mesomerism. For example, the allyl cation (6) is more stable than the propyl cation (7) which is reflected by greater reactivity of allyl isothiocyanate than propyl isothiocyanate (Zahradnik, 1959).




(6)



(7)


In the case of 2-benzylidenecyclohexyl isothiocyanate, the phenyl ring will further stabilize the allylic cation (8) which should enhance the alkylating properties of the isothiocyanate via the S_N1 mechanism. Electron-donating substituents in the ortho




or para positions of the aromatic ring should increase the stability of the carbonium ion. For example, a dimethylamino group in the para position of the phenyl ring would extend the mesomerism, giving a more stable carbonium ion.

Maximum resonance stabilization of the carbonium ion (8) is expected when the conjugated system is coplanar, which allows for maximum overlap of atomic orbitals. Bulky substituents in the ortho position of the phenyl ring would be expected to force the phenyl ring out of planarity with the rest of the conjugated system, resulting in lower resonance stabilization. The presence of a chlorine atom in the ortho position of the phenyl ring would be expected to exert a steric effect sufficient to twist the phenyl ring out of coplanarity with the ethylenic group. This effect can be observed and the angle of twist determined by ultraviolet spectroscopy and Braude's equation (Braude, 1955).

A further reason for the preparation of substituted 2-benzylidene-cyclohexyl isothiocyanates is that transportation to the site of action may be dependent on coplanarity between different groups of the molecule. It has been shown that geometrical isomers with varying degrees of planarity have different adsorption properties on non-biological surfaces. For example, Zechmeister and McNeely (1942) reported that stilbene (9) possessed higher adsorption properties on an alumina column than the corresponding Z isomer, isostilbene (10).




(9)




(10)

In certain cases, biological activity resides in the isomer displaying a lack of planarity. (Z)-Cinnamic acid (11) displays activity as a plant growth regulator whereas the corresponding E isomer (12) is inactive (Haagen-Smit and Went, 1935). Alternatively,




(11)




(12)

biological activity may be greater in the planar molecule. Compound (13) has the pyridine ring coplanar with the double bond whereas the other isomer (14) is prevented by steric hindrance from demonstrating this coplanarity. In this case compound (13) has a greater antihistaminic activity than compound (14) (Adamson *et al.*, 1951).




(13)



(14)
















Comparison of the biological activity of 2-benzylidenecyclohexyl isothiocyanate and its substituted derivatives should indicate whether planarity of the molecule enhances reactivity. A comparison of the biological activity of the corresponding substituted and unsubstituted ketones and ketoximes may also indicate whether activity is favored by coplanarity.

In addition it would be interesting to have 2-benzylcyclohexyl isothiocyanate (15) screened to determine if biological activity is decreased by saturation of the olefinic bond of 2-benzylidenecyclohexyl isothiocyanate, analogous to the decreased activity of propyl isothiocyanate as compared to allyl isothiocyanate.




(15)

The proposed route for the synthesis of the isothiocyanates in this program is as shown in Scheme 1. The first stage in this




Scheme 1 Proposed route for the synthesis of substituted 2-benzylidenecyclohexyl isothiocyanates

synthesis is the preparation of the substituted 2-benzylidenecyclohexanones (16), which are α,β -unsaturated ketones, a class of compounds known to be alkylating agents. The substituted 2-benzylidenecyclohexanones (16) represent more rigid cyclic analogs of the flexible open chain derivatives of 1-phenyl-1-nonen-3-one (20). The screening results against L-1210 lymphoid leukemia for derivatives of (16) and (20)¹ will hopefully demonstrate whether rigidity or flexibility is favored for optimum antileukemic activity in these compounds.



(16)




(20)

¹Taylor (1972).

It is generally considered that drug molecules become associated at receptor surfaces by the alignment of certain functions on the molecule with complementary sites on the receptor. The receptor site is the component of the cell with which the drug molecule interacts. Most effective drug-receptor interaction would be expected with rigid molecules in which the distance between functions important for interaction at the receptor is similar to the distance between the complementary sites on the receptor surface. However, a rigid molecule that does not possess the correct molecular dimensions cannot associate at the receptor surface since it has little or no capacity for changing to a more favourable geometry. In contrast, a less rigid molecule is capable of adopting a wide range of conformations, one of which may possess molecular dimensions complementary to the receptor.


The ability of many α,β -unsaturated ketones to react with sulphhydryl compounds was discovered by Posner (1902, 1904). He found that α,β -unsaturated ketones of general structure (21) undergo addition reactions most readily when R^1 is an aromatic radical and R^2 or R^3 is a hydrogen atom.



(21)

antibacterial activities of clavacin and penicillic acid depend on their reaction with sulfhydryl groups was established by Geiger and Conn (1945). They found that both compounds were inactivated by sulfhydryl compounds. Clavacin was inactivated by thioglycolate and by thiosulfate most effectively while penicillic acid was inactivated by cysteine and thioglycolate. Geiger and Conn (1945) synthesized a number of α,β -unsaturated ketones using Posner's model structure (21) as a guide in an attempt to discover α,β -unsaturated ketones with antibacterial activity similar to clavacin and penicillic acid. The most active compound, acrylophenone, fulfilled the structural requirements of (21) perfectly, since here R^1 is a phenyl group, and both R^2 and R^3 are hydrogen atoms. It demonstrated significant bacteriostatic activity and showed fungistatic activity of the same order of magnitude as clavacin. Acrylophenone was also inactivated by both cysteine and thioglycolate. Thus Geiger and Conn concluded that the antibiotic activity of clavacin and penicillic acid, as well as certain synthetic α,β -unsaturated ketones, such as acrylophenone, was due to their reaction with the sulfhydryl groups of bacterial enzyme systems or with sulfhydryl-containing metabolites essential to the bacteria.

The reaction of α,β -unsaturated lactones with thiols has been suggested to play a key role in several biological growth-regulatory phenomena. The selective growth-inhibitory action of δ -hexenolactone (25) on certain animal tissues was shown to be antagonized by cysteine (Hauschka et al., 1945).





(25)


Since then the search for tumor inhibitors of plant origin has led to the isolation and characterization of a number of sesquiterpene lactones (Kupchan, 1970) that exhibit growth inhibitory activity in vivo against animal tumor systems and in vitro against KB cells. The functional group which is common to these compounds is the α -methylene- γ -lactone grouping. A study of the reactions of tumor-inhibitory conjugated α -methylene lactones with model biological nucleophiles revealed that sulfhydryl compounds were the most reactive of the nucleophiles investigated, which supports the view that a Michael-type addition of sulfhydryl-bearing compounds may play a significant role in the mechanisms by which the lactones exert their biological activities (Kupchan et al., 1970a). The tumor-inhibitory α -methylene lactones have been shown to inhibit the sulfhydryl enzyme, phosphofructokinase, and evidence has been presented to indicate that the inhibition resulted from their reaction with the sulfhydryl groups of the enzyme (Hanson et al., 1970).

Kupchan and coworkers (1970b) investigated the reactions of endocyclic α,β -unsaturated γ -lactones such as (26) with various sulfhydryl compounds. Cysteine appeared to be the most reactive of

the sulfhydryl compounds investigated. They also found that the exocyclic unsaturated lactone (27) in elephantopin (28) reacted much faster with cysteine than unsaturated endocyclic lactones such as (26). A rate ratio of exocyclic to endocyclic unsaturated lactones of the order of 10^3 was suggested.




(27)




(28)

It has been shown that α,β -unsaturated lactones react with amines in an analogous manner. The addition of dimethylamine to compound (26) has been found to occur in solution (Jones and Young, 1966). The exocyclic unsaturated lactone present in costunolide (29) reacts with dimethylamine to give a stable Michael adduct (Hiremath *et al.*, 1968). Baltzly

and coworkers (1955) studied the addition of a number of secondary amines to cyclic and open-chain analogs of 2-benzylidenecyclohexanone. In these systems the steric requirements of the amine appeared to be quite critical with only cyclic amines and methyl secondary amines adding well. The basicity of the amines appeared to have little relation to the yield of addition product. Such bases as piperidine gave 80-90% of the addition compound (30).



(29)



(30)

In a study of the relative nucleophilic reactivities of amino groups and mercaptide anions in addition reactions with α,β -unsaturated compounds, Friedman *et al.* (1965) found that, at comparable pK_a values and steric environments, mercapto anions are about 280 times more reactive than amino groups.